Coronavirus disease 2019 or COVID-19 is an infectious disease declared as a global pandemic by the World Health Organization (WHO) in 2020. As of August 2022, COVID-19 had infected at least 590 million people and caused at least 6.43 million deaths worldwide. There are multiple strains of the virus with changing virulency and infectivity. There are many different types of COVID vaccines available, namely the mRNA vaccines, virus vectored vaccines, inactivated virus vaccines, protein subunit vaccines and virus-like particles vaccines. We offer the inactivated virus covid vaccine (Vero Cell), the spike protein recombinant vaccine as well as the variant specific inactivated vaccine.
SARS-COV-2 Vaccine (Vero Cell), Inactivated
Developed by SinoPharm, our vaccine has been approved by the World Health Organization (WHO) global Emergency Use Listing (EUL) in 2021. It is adjuvanted with aluminium hydroxide to strengthen the immune system1.
It is recommended for use in individuals above 18 years old. A large multi-country Phase 3 trial has shown that 2 doses, administered at an interval of 21 days, have an efficacy of 79% against symptomatic SARS-CoV-2 infection 14 or more days after the second dose. Vaccine efficacy against hospitalization was 79%
99.52 % of the vaccine recipients developed seroconversion of neutralising antibodies to render the disease useless after two doses
The WHO recommended two-doses with an interval of 3-4 weeks. If the second dose is administered less than 3 weeks after the first, the dose does not need to be repeated. If administration of the second dose is delayed beyond 4 weeks, it should be given at the earliest possible opportunity. A third additional dose should be offered to persons aged 60 and above, or severe and moderately immunocompromised individuals with continuous safety monitoring. Booster doses can be considered 4-6 months after the primary series of vaccines. [5]
Sinopharm has been the leading supplier of vaccine donations from China, supplying 103 million doses of donated vaccine to 79 countries. On May 7, Sinopharm became the first Chinese COVID-19 vaccine to receive approval from WHO for emergency use. [6]
GEN2-Recombinant COVID-19 Vaccine
Recombinant protein effectively defends against the COVID-19 virus. This approach builds immunity against the novel coronavirus by utilizing the virus’ spike proteins.
Our vaccine is currently approved for use in the United Arab Emirates and is undergoing clinical trials in China to evaluate the safety and tolerability in healthy patients aged 18 years and older1.
SARS-CoV 2 (Omicron Variant) Vaccine, Inactivated
Our vaccine is currently approved for clinical trials as a booster shot in Hong Kong and United Arab Emirates3. It is currently undergoing clinical study in China, Hubei Province to evaluate the immunogenicity and safety of the vaccine4.
The COVID-19 pandemic has underscored the importance of research and development in preparation for future pandemics. In Sino-Innovax, we focus on predicting new infectious landscapes and challenge the frontiers of vaccine science. We are open to collaboration with innovative and cutting-edge technologies and products which align with our strategic interest.
Plasma being the largest component in the human blood, helps individuals to stay healthy. Plasma-derived products are prepared from the separation of proteins in the human plasma and are vital in the treatment of autoimmune diseases. a. Human Immunoglobulin (pH4) for Intravenous Injection IVIG targets a wide range of autoimmune diseases […]
Our parent company China National Biotec Group (CNBG) is the 6th largest vaccine manufacturer in the world. CNBG has the capacity of manufacturing approximately 700 million doses of 50 various human vaccines (a year?) Sino-Innovax is also committed to benefit people from all around the globe through our constant development of efficient and novel vaccines. […]